Vicarious Surgical (RBOT) AI Stock Analysis

• Market Cap: $18.86M
• Dividend Yield: N/A
• Average Volume (3M): 90.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.47
• Revenue Growth: N/A
• EPS Growth: 15.03%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -1.91
• Shares Outstanding: 6,463,251
• 10 Day Avg. Volume: 138,739
• 30 Day Avg. Volume: 90,387
• PEG Ratio: 0.05
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.54
• Enterprise Value/Market Cap: 1.42
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -30.03
• Enterprise Value/Ebitda: -0.51
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▼(-5.66% Downside)

The score is held down primarily by very weak financial performance (no revenue, large ongoing losses, heavy cash burn, and sharply reduced equity). Technicals also remain unfavorable with a clear longer-term downtrend and negative MACD. Offsetting factors include cost-cutting progress and improved cash-burn guidance plus financing actions, but these are not yet enough to outweigh the current funding and execution risk.

Positive Factors

Strategic software outsourcing partnership

Outsourcing core software development to a scaled engineering partner is a structural execution change. It reallocates fixed development burden, lets internal teams focus on system integration and innovation, and can materially speed progress toward design freeze and clinical readiness.

Improved cash-burn guidance and cost discipline

A multi-year reduction in projected cash burn driven by headcount cuts and outsourcing reflects durable operational tightening. Lower structural burn reduces financing frequency and gives more runway to reach key milestones like design freeze, improving odds of orderly commercialization execution.

Warrant exercise approval enhances capital optionality

Stockholder approval to exercise warrants is a structural financing lever that can bring incremental equity if exercised. This improves long-term capital flexibility, can shore up the balance sheet without new debt, and lowers refinancing pressure as the company advances its surgical system.

Negative Factors

Pre-commercial status with no revenue

Lack of product revenue is a fundamental constraint: the business remains pre-commercial, preventing validation of pricing, share economics, and recurring consumable margins. Continued reliance on external funding increases execution and solvency risk and delays the path to sustained profitability.

High recurring cash burn and negative free cash flow

Persistent, sizeable negative operating and free cash flow creates structural dependency on capital markets. Regular fundraises can dilute shareholders, constrain investments in commercialization, and heighten the risk that development timetables slip if access to financing tightens.

Eroding equity base increases solvency fragility

Sharp equity erosion materially weakens the company's financial cushion against losses. Even moderate absolute debt becomes more consequential, reducing resilience to delays or cost overruns, limiting strategic options, and making future financing more dilutive or costly if performance slips.

Vicarious Surgical Business Overview & Revenue Model

Company Description

Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Vicarious Surgical makes money primarily through the sale and leasing of its robotic surgical systems to hospitals and surgical centers. The company may also generate revenue through service contracts and maintenance agreements, ensuring the optimal functionality of its robotic platforms. Additionally, Vicarious Surgical could engage in strategic partnerships with healthcare providers and institutions to expand the adoption of its technology. These partnerships may involve collaborative research, co-development of surgical techniques, and training programs for surgeons. Furthermore, as the company's technology advances, it may explore revenue opportunities through software licensing, offering AI-driven analytics and insights as a service to enhance surgical performance and patient outcomes.

Vicarious Surgical Financial Statement Overview

Summary

Financial profile is very weak: TTM shows no revenue, large operating losses (EBIT about -$55.7M) and net loss (about -$53.6M), and heavy cash burn (operating cash flow about -$47.5M; free cash flow about -$47.8M). Equity has compressed sharply to about $14.1M (from $46.7M in 2024 annual), increasing financing and solvency risk despite only moderate absolute debt (~$12.9M; D/E ~0.57).

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued heavy operating losses (EBIT about -$55.7M; net loss about -$53.6M), indicating the business is still pre-commercial or not yet scaling. Profitability has deteriorated versus 2024 annual (net loss about -$63.2M) mainly through persistent high operating costs and negative gross profit in both periods. The only relative positive is a modest improvement in the absolute net loss versus 2023–2024, but overall earnings quality and margin profile remain very weak due to the lack of revenue.

Balance Sheet

Leverage is moderate in TTM (Trailing-Twelve-Months) with debt-to-equity around 0.57 and total debt of about $12.9M, but the bigger issue is rapid balance sheet shrinkage: equity has fallen sharply from about $98.0M (2023 annual) and $46.7M (2024 annual) to about $14.1M in TTM, consistent with ongoing losses and cash burn. Return on equity is deeply negative in TTM, signaling meaningful capital erosion risk. While debt is not extreme in absolute dollars, the reduced equity base increases financial fragility.

Cash Flow

Cash generation is weak: TTM (Trailing-Twelve-Months) operating cash flow is about -$47.5M and free cash flow about -$47.8M, showing substantial ongoing cash burn. Free cash flow worsened versus 2024 annual (about -$50.1M) and remains consistently negative across the history provided, implying continued reliance on external funding. A positive note is that free cash flow roughly tracks net loss (free cash flow to net income ~1.0), suggesting losses are largely reflected in cash, but the scale of burn remains a key risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-894.00K	-2.11M	-1.85M	0.00	0.00	0.00
EBITDA	-52.57M	-61.12M	-69.19M	6.47M	-34.80M	-12.83M
Net Income	-53.59M	-63.22M	-71.07M	5.16M	-35.21M	-12.88M
Balance Sheet
Total Assets	29.35M	67.72M	119.86M	140.29M	181.68M	17.79M
Cash, Cash Equivalents and Short-Term Investments	13.41M	49.10M	98.18M	116.21M	173.51M	16.87M
Total Debt	12.89M	13.79M	14.83M	15.69M	1.34M	110.00K
Total Liabilities	15.26M	21.02M	21.89M	29.25M	98.59M	935.00K
Stockholders Equity	14.09M	46.70M	97.97M	111.05M	83.09M	16.85M
Cash Flow
Free Cash Flow	-47.77M	-50.14M	-63.98M	-66.56M	-34.59M	-12.16M
Operating Cash Flow	-47.47M	-49.96M	-62.30M	-61.21M	-33.30M	-12.04M
Investing Cash Flow	43.51M	6.86M	-45.78M	-5.35M	-1.29M	13.20M
Financing Cash Flow	72.84K	8.00K	44.70M	9.14M	192.16M	13.52M

Vicarious Surgical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBOT, the sentiment is Negative. The current price of 2.65 is above the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.83, and below the 200-day MA of 6.11, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.06 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RBOT.

Vicarious Surgical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INSP	69 Neutral	$2.68B	63.26	6.54%	―	16.81%	34.90%
XTNT	66 Neutral	$93.10M	65.20	3.64%	―	16.88%	―
LIVN	63 Neutral	$3.39B	-15.49	-17.63%	―	8.97%	-1024.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RBOT	45 Neutral	$18.86M	-0.29	-148.93%	―	―	15.03%
OM	45 Neutral	$96.10M	-0.41	-92.33%	―	4.65%	68.71%
PRCT	41 Neutral	$1.70B	-19.75	-27.22%	―	50.07%	21.22%

Vicarious Surgical Corporate Events

Vicarious Surgical Stockholders Approve Warrant Exercise Proposal

On January 9, 2026, Vicarious Surgical Inc. held a special meeting of stockholders at which holders of Class A and Class B common stock, representing approximately 78.18% of the company’s total voting power, formed a quorum to vote on a single proposal. Stockholders overwhelmingly approved the exercise of warrants issued on October 7, 2025 to purchase up to an aggregate of 2,300,000 shares of Class A common stock, a step that positions the company to potentially strengthen its capital base and financial flexibility as it advances its surgical robotics business.

The most recent analyst rating on (RBOT) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.

Vicarious Surgical Announces 2026 Cash Burn Guidance

On December 12, 2025, Vicarious Surgical Inc. entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of its Class A common stock, subject to certain conditions. This agreement allows the company to manage the sale parameters and provides flexibility in raising capital. Additionally, on December 15, 2025, Vicarious Surgical announced its 2026 cash burn guidance, projecting a reduction to $35 million, reflecting a $10 million improvement from 2025. This improvement is attributed to cost management strategies, including headcount reductions and strategic outsourcing, which aim to support the company’s goal of achieving a design freeze on its surgical system by the end of 2026.

The most recent analyst rating on (RBOT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.

Vicarious Surgical Announces Improved Cash Burn Outlook

On December 1, 2025, Beverly Huss and Randy Clark resigned from Vicarious Surgical‘s Board of Directors as part of a decision to reduce the board’s size from nine to seven members. This change did not stem from any disagreements with the company’s operations. Subsequently, Joseph Doherty, Fuad Ahmad, and Victoria Carr-Brendel were appointed to new roles within the board’s committees. On December 3, 2025, Vicarious Surgical announced an improved cash burn outlook for 2025, reducing it from $50 million to $45 million due to disciplined cost management. This financial update aligns with the company’s strategic focus on operational efficiency and supports its long-term goals.

The most recent analyst rating on (RBOT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.